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Identity 
Other names: ROCK-II 




ROCK2 was first identified as a target of active RhoA 
in an expression screening assay from a rat brain cDNA 
library (Leung et al. 1995). 
Description 
The ROCK2 gene is 4164 bp long which encodes 1388 
amino acids producing a protein of 160 kDa (UniGene: 
Hs.681743).  
The ROCK2 gene comprises 33 exons. 
Protein 
Note 
ROCK2 is a 160 kDa serine/threonine kinase which is 
composed of a kinase domain (44-415 aa) at the  
amino-terminus, a rho-binding domain (981-1046 aa), 
and a pleckstrin homology (PH) domain with a 
cysteine-rich region at the carboxyl-terminus (1152-
1350 aa).  
A coiled-coil inhibitory structure was predicted to form 
between the kinase domain and the PH domain. 
ROCK2 exists in an auto-inhibitory form which could 
be released when active form of RhoA (RhoA-GTP) 
binds to the RBD domain of ROCK2. The functional 
domains of ROCK2 have unique roles such as protein-
protein interaction, cellular localization, and regulation 
of ROCK2 activity. Kinase domain of ROCK2 is the 
key domain conferring the most important function of 
ROCK2 which is the phosphorylation and activation of 
its downstream substrates (Leung et al., 1995).  
PH domain of ROCK2 is responsible for lipid binding 
and membrane localization of ROCK2 (Miyazaki et al.,
2006).  
PH domain of a ROCK2 homolog also facilitates the 
interaction with other proteins such as filamin A, a 
protein critical to actin cytoskeleton remodeling (Ueda 
et al., 2003). 
 
Schematic diagram of ROCK2. RBD: rho-binding domain; PH: pleckstrin homology; C1: cysteine-rich region. 
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Expression 
Very few studies have demonstrated the distinctive 
roles of ROCK1 and ROCK2; however, their 
differential tissue distribution indicates that they 
participate in different physiological functions. ROCK1 
and ROCK2 are ubiquitously expressed in all tissues. 
Earlier studies using Northern blot analysis 
demonstrated that ROCK1 mRNA expression was 
especially abundant in testis, liver, and lung while 
ROCK2 mRNA expression was especially abundant in 
brain and muscle (Leung et al., 1996). 
Regulation: The most common regulatory mechanism 
of ROCK2 is mediated by RhoGTPases whose activity 
exchanges between a GTP-bound active form and a 
GDP-bound inactive form. RhoA-GTP binds to the 
RBD domain of ROCK and releases the kinase domain 
of ROCK leading to the activation of ROCK (Leung et 
al., 1995). In addition to this classical model of activity 
regulation, ROCK2 can also be activated by lipids such 
as arachidonic acid (Feng et al., 1999). The ROCK2 
kinase domain can also be released when the C-
terminus of ROCK2 is cleaved by granzyme B 
(Sebbagh et al., 2005). Furthermore, Polo-like kinase-1 
(Plk1) interacts with and phosphorylates ROCK2 at 
Threonine 967, Serine 1099, Serine 1133, and S1374 
and activates ROCK2 (Lowery et al., 2007). 
Recent studies have demonstrated that ROCK2 is also 
regulated at the expression level. Two microRNAs 
(miRNAs), miR-139 and miR-124, have independently 
been shown to interact with the 3'untranslated region of 
ROCK2 and subsequently suppress ROCK2 expression 
in hepatocellular carcinoma (HCC) cell lines (Wong et 
al., 2011; Zheng et al., 2012). MiR-139 and miR-124 
have been shown to be downregulated in human HCCs 
and their expression levels inversely correlated with 
ROCK2 protein expression in human HCC samples 
(Wong et al., 2011; Zheng et al., 2012). 
Localisation 
ROCK2 is mainly found in the cytoplasm in most cell 
types. It was reported that overexpression of a 
dominant-active form of RhoA re-localized ROCK2 to 
the membranous actin filaments in a cervical cancer 
cell line, HeLa (Leung et al., 1995). A study has also 
shown that ROCK2 could be found in the nuclei in 
multiple cell types such as human keratinocytes, mouse 
mammary epithelial cells, osteoblasts, and mouse 
fibroblasts (Tanaka et al., 2006). ROCK2 was also 
found to be located in the centrosome in fibroblasts 
(Ma et al., 2006; Wang et al., 2011). 
Function 
ROCK2 are responsible for many key cellular 
processes including cell migration and invasion (Croft 
et al., 2004), apoptosis (Sebbagh et al., 2005), 
centrosome duplication (Ma et al., 2006), and 
cytokinesis (Lowery et al., 2007). 
 
The best well-characterized function of ROCK is 
contributed by the kinase domain for its ability to 
phosphorylate the serine/threonine residues of 
downstream substrates that are important for actin 
cytoskeleton organization.  
The most well-known substrates of ROCK include 
myosin light chain 2 (MLC2) and myosin phosphatase 
1 (MYPT1) which regulate actomyosin contractility in 
cells (Amano et al., 1996). Other ROCK substrates 
include cofilin and LIM kinases, responsible for actin 
polymerization and depolymerization (Yang et al., 
1998; Sumi et al., 1999; Ohashi et al., 2000; Sumi et 
al., 2001); vimentin (Goto et al., 1998), responsible for 
actin filament formation; adducin, responsible for 
membrane ruffles formation (Fukata et al., 1999); 
calponin, responsible for actin filament binding 
(Kaneko et al., 2000); ezrin, responsible for anchoring 
the cytoskeleton to the cell membrane and the 
formation of focal adhesion molecules (Matsui et al.,
1998; Tran Quang et al., 2000). 
In addition to cell movement, ROCK2 was shown to be 
important in keratinocyte differentiation (McMullan et 
al., 2003). Also, Plk1-mediated phosphorylation and 
activation of ROCK2 induced cytokinesis (Lowery et 
al., 2007).  
Nuclear function of ROCK2 was first reported when 
ROCK2 was found to be a binding partner of p300 
acetyltransferase (Tanaka et al., 2006). Nuclear 
ROCK2 phosphorylated p300 and activated p300-
mediated transcription (Tanaka et al., 2006). 
Centrosomal ROCK2 interacted with 
nucleophosmin/B23 and BRCA2 proteins for 
centrosome duplication (Ma et al., 2006; Wang et al., 
2011). 
ROCK2 also regulates the extracellular matrix. 
Expression of conditional active ROCK2 construct has
been shown to activate MYPT and MLC and drive 
actomyosin contraction in mouse skin, thereby 
modifying the ECM through increased collagen 
deposition and tissue stiffness (Samuel et al., 2011).  
Along with the ECM modification, activation of 
ROCK2 may also increase nuclear accumulation and 
activity of β-catenin.  
Activation of β-catenin can elevate epidermal cell 
proliferation rate, subsequently contributing to 
epidermal hyperplasia and tumor growth (Samuel et a., 
2011). 
Homology 
ROCK2 shares close homology with another protein 
called ROCK1. ROCK1 and ROCK2 are 65% 
homologous in human; particularly, their kinase 
domains are 87% homologous (Leung et al., 1996). 
Due to their high degree of homology, ROCK1 and 
ROCK2 are regulated by common mechanisms and 
share many common substrates. 
 
 










ROCK, in general, has been shown to be implicated in 
various cancer cell line models; however, only a few




In a subcutaneous tumor model in nude mice, 
conditional expression of active ROCK2 construct in 
colorectal cancer cell lines has been demonstrated to 
enhance angiogenesis and cancer cell invasion into the 
surrounding stromal tissues (Croft et al., 2004). 
Hepatocellular carcinoma 
Note 
ROCK2 protein was shown to be over-expressed in 
54% (22/41 cases) of human hepatocellular carcinoma 
(HCC) as compared with their corresponding non-
tumorous liver tissues by Western blot analysis (Wong 
et al., 2009). Over-expression of ROCK2 in HCC was 
associated with the presence of tumor microsatellite 
formation, an important clinicopathological feature of 
aggressive HCC and an indicator of intrahepatic 
metastasis in human HCC (Wong et al., 2009). 
Knockdown of ROCK2 in human HCC cell lines 
suppressed stress fiber and focal adhesion formation, as 
well as actomyosin contractility in HCC cells, thereby 
retarding HCC cell invasion in vitro and in vivo (Wong 
et al., 2009). 
Squamous skin carcinomas 
Note 
Immunohistochemical study using an antibody with 
reactivity towards both ROCK1 and ROCK2 indicates 
that high ROCK expression was detected in 40 cases of 
human squamous skin carcinomas (Samuel et al., 
2011). Along with this finding, phosphorylation of 
MYPT, as a reflection of ROCK activity, was also 




ROCK2 protein was shown in Western blot analysis to 
be overexpressed in testicular cancers as compared to 
non-tumorous tissues in a cohort of 57 patients (Kamai 
et al., 2004). ROCK2 protein expression was 
significantly higher in patients with recurrent testicular 
cancers than those without sign of recurrence after 
treatment (Kamai et al., 2004). 
Breast cancer 
Note 
It has long been challenging to detect the ROCK  
activity in human clinical specimens owing to the fact 
that ROCK activity declines rapidly in clinical 
specimens after resection. Also, the phosphorylation 
sites in ROCK, which truly reflect its activity status, 
have not been identified or extensively studied. 
Recently, a study has demonstrated that the activity 
status of ROCK2 can be reflected by the 
phosphorylation level of ROCK2 at Ser1366. 
Immunohistochemical staining shows that 
phosphorylation of ROCK2 at Ser1366 was increased in 
2 cases of breast cancer tissues as compared to their 
normal counterparts (Chuang et al., 2012). 
To be noted 
Drugs 
Multiple ROCK inhibitors are available; but none of 
these inhibitors specifically discriminate the two 
homologs. The common commercially available ROCK 
inhibitors are pyridine or isoquinoline-based small 
molecule inhibitors. Both inhibitors compete for the 
ATP-binding sites of ROCK. Y27632 is the most 
commonly used pyridine-based ROCK inhibitor and 
has been shown to possess significant selectivity 
towards ROCK than other protein kinases (Davies et 
al., 2000; Ishizaki et al., 2000). Fasudil, the most 
common isoquinoline-based ROCK inhibitor, was first 
used in the clinic in 1993 for the treatment of cerebral 
vasospasm in Japan and was later discovered to possess 
inhibitory effect on ROCK (Shibuya and Suzuki, 
1993). Clinical experience of fasudil shows that it is 
well tolerated in the human body; however, it is les 
selective than Y27632. Therefore, Y27632 is more 
widely used in basic research whilst fasudil is more 
widely used in the clinic. The half-life of Y27632 in
vivo is around 2 hours (Takamura et al., 2001). Studies 
have demonstrated that continuous delivery of Y2763 
by osmotic pump profoundly suppressed the formation 
of metastases in syngeneic rats that were peritoneally 
implanted with rat hepatoma cells or in SCID mice that 
were orthotopically implanted with human HCC cells 
(Itoh et al., 1999; Takamura et al., 2001). So far, 
ROCK inhibitors have not been used in the clinic for 
cancer treatment. Further investigation on the efficacy 
of ROCK inhibitors in cancer treatments is much 
warranted. 
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